

Submission on the consultation: Discontinuing pre-market evaluation of herbal component names (HCNs)

Date: 11th January 2018

To:

Complementary Medicines Evaluation Section
Complementary and Over-the-counter Medicines Branch
Therapeutic Goods Administration
PO Box 100
Woden ACT 2606

From:

Michael Gepp
Scientific Affairs Manager
Pathway International Pty Ltd
PO Box 6185
Frenchs Forest NSW 2086
Telephone: 02 9984 2700
E-mail: michael@pathway.net.au
Website: www.pathway.net.au

General comments

We support regulatory option 2 to discontinue the pre-market evaluation of pre-market evaluation of herbal component names (HCNs).

It should also be noted that HCNs are not currently visible in the public ARTG entry so there is no impact on consumers or other users that utilise the ARTG to search for product based information.

In addition to ARTG entries being updated, herbal proprietary ingredients that include HCNs will need to be updated to have those HCNs removed from their details.